Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 920-925

  Peña Sagredo, José L ^a   Fariñas, Maria C ^b   Perez Zafrilla, Beatriz ^c   Cruz Valenciano, Ana ^d   Crespo, Manuel ^d   Joven Ibañez, Beatriz ^e   Riera, Elena ^f   Manero Ruiz, Francisco J ^g   Chalmeta, Inmaculada ^h   Hernández, Ma Victoria ⁱ   Rodríguez Gómez, Manuel ^j   Maíz, Olga ^k   López, Ruth ^l   Cobo, Tatiana ^m   Pita, Julia ⁿ   Carmona, Loreto ^c   Gonzalez Gay, Miguel A ^o  

^a IDIVAL   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIDAD DE INVESTIGACIÓN   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j Hospital de Orense   (Spain)

^k HOSPITAL DONOSTIA   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁿ Microbiology Division   (Spain)

^o HOSPITAL XERAL CALDE   (Spain)

more..

Author keywords

Non typhi Salmonella infection; Rheumatic disease; TNF antagonists

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CIPROFLOXACIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSCESS; ACUTE GASTROENTERITIS; ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL TRANSMISSION; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENDOCARDITIS; FALSE ANEURYSM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REGISTER; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SALMONELLA; SALMONELLOSIS; SEPSIS; SPAIN; SPONDYLOARTHROPATHY;

EID: 76649113082     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
2. ATZENI F, BENDTZEN K, BOBBIO-PALLAVICINI F et al.: Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol 2008; 26 (Suppl. 48): S67-73.
3. SOKKA T, ABELSON B, PINCUS T: Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S35-61.
4. LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
5. IMPERATO AK, BINGHAM CO 3RD, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 (Suppl): S108-14.
6. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45
7. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999; 130: 478-86.
8. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
9. FIGUEIREDO IT, MOREL J, SANY J, COMBE B: Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 18-23.
10. CARMONA L, GONZALEZ-ALVARO I, BALSA A, BELMONTE MA, TENA X, SANMARTI R: Rheumatoid arthritis in Spain: Occurrence of extraarticular manifestations and estimates of disease severity Ann Rheum Dis 2003; 62: 897-900.
11. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
12. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ-ANDRADE A, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-12.
13. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
14. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
15. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERJA A et al.: Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1644-6.
16. DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: British Society for Rheumatology Biologics Register. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
17. GÓMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD; and the BIOBADASER GROUP: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter activesurveillance report. Arthritis Rheum 2003;48: 2122-7.
18. RUYSSEN-WITRAND A, GOSSEC L, SALLIOT C et al.: Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007; 25: 430-6.
19. CARMONA L, GÓMEZ-REINO JJ, RODRÍGUEZ-VALVERDE V et al.: BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
20. BOWIE VL, SNELLA KA, GOPALACHAR AS, BHARADWAJ P: Listeria meningitis associated with infliximab. Ann Pharmacother 2004;38: 58-61.
21. GLUK T, LINDE HJ, SCHOLMERICH J, MULLER-LANDER U, FIEHN C, BOHLAND P: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases Arthritis Rheum 2002; 46: 2255-7.
22. JOOSTEN AA, VAN OLFFEN GH, HAGEMAN G: Meningitis for Listeria monocytogenes as a complication infliximab therapy. Ned Tijdschr Geneeskd 2003; 147: 1470-2.
23. SCHETT G, HERAK P, GRANINGER W, SMOLEN JS, ARINGER M: Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005; 43: 2537-41.
24. KATSAROLIS I, TSIODRAS S, PANAGOPOULOS P et al.: Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37: 304-5.
25. NETEA MG, RADSTAKE T, JOOSTEN LA, VAN DER MEER JW, BARRERA P, KULLBERG BJ: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003; 48: 1853-7.
26. PEÑA-SAGREDO JL, HERNÁNDEZ MV, FERNANDEZ-LLANIO N et al.: Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008; 26: 854-9.
27. BIOBASDASER SCIENTIFIC COMMITTEE: Spanish registry of adverse events of biological therapies in rheumatic diseases. Rev Esp Reumatol 2002; 29: 292-9.
28. PÉREZ-CIORDIA I, FERRERO M, SÁNCHEZ E, ABADÍAS M, MARTÍNEZ-NAVARRO F, HERRERA D: Salmonella enteritis in Huesca. 1996-1999. Enferm Infecc Microbiol Clin 2002; 20: 16-21.
29. BONGARTZ T, SUTTON A.J, SWEETING MJ, BUCHAN I, MATTERSON EL, MONTORI V: Anti-TNF Antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trial. JAMA 2006; 295:2275-85.
30. FERNÁNDEZ-AYALA M, NAN D, GUTIERREZ JA, FARIÑAS MC: Postoperative mediastinitis due to Salmonella. Scand J Infect Dis 2003; 35: 67-8.
31. HOHMANN EL: Non-typhoidal salmonellosis. Clin Infect Dis 2001; 32:263-9.
32. MASTROENI P, HARRISON JA, ROBINSON JH, CLARE S, KHAN S, MASKELL DJ: Interleukin-12 is required for control of the growth of attenuated aromatic-compound dependent Salmonellae in BALB/c mice: role of gamma-interferon and macrophages activation. Infect Immun 1998; 66: 4767-76.
33. EVEREST P, ROBERTS M, DOUGAN G: Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor alpha p55 receptor. Infect Immun 1998; 66: 3355-64.
34. HESS J, LADEL C, MIKO D, KAUFMANN SH: Salmonella typhimurium aroA-infection in gene-targeted immunodeficient mice: major role of CD4+ TCR-alpha beta cells and IFNgamma in bacterial clearance independent of intracellular location . J Immunol 1996; 156:3321-6.
35. JOUANGUY E, DOFFINGER R, DUPUIS S, PALLIER A, ALTARE F, CASANOVA JL: IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11: 346-51.
36. MASTROENI P, ARENA A, COSTA GB, LIBERTO MC, BONINA L, HORMAECHE CE: Serum TNF in mouse typhoid and enhancement of a Salmonella infection by anti-TNF alpha antibodies. Microb Pathog 1991; 11:33-8.
37. NAKANO T, OHARA O, TERAOKA H, ARITA H: Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS lett 1990; 261: 171-4.
38. NAUCIEL C, ESPINASSE-MAES F: Role of gamma interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60: 450-4.
39. VÁZQUEZ-TORRES A, FANTUZZI G, EDWARDS CK 3RD, DINARELLO CA, FANG FC: Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci USA 2001; 98: 2561-5.
40. YAMAMOTO T, SASHINAMI H, TAKAYA A et al.: Disruption of the genes for ClpXP protease in Salmonella enterica serovar Typhimurium results in persistent infection in mice, and development of persistence requires endogenous gamma interferon and tumor necrosis factor alpha. Infect Immun 2001; 69: 3164-74.
41. DYBING JK, WALTERS N, PASCUAL DW: Role of endogenous interleukin-18 in resolving wild-type and attenuated Salmonella typhimurium infections. Infect Immunol 1999;67: 6242-8.
42. ARAI T, HIROMATSU K, NISHIMURA H et al.: Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection. Immunology 1995; 85:381-8
43. MINOHARA Y, KATO T, CHIBA M et al.: A rare case of Salmonella soft-tissue abscess. J Infect Chemother 2002; 8:185-6.